Target intelligence / Profile preview

Neurogenin-3 (NEUROG3) (NEUROG3)

Target
NEUROG3
Molecular classification
Transcription factor, Basic helix-loop-helix (bHLH) protein
01

Overview

Neurogenin-3 (NEUROG3) is a basic helix-loop-helix (bHLH) transcription factor that serves as the master regulator for the differentiation of endocrine progenitor cells in both the pancreas and the intestinal tract (UniProt P78337). During embryonic development, its transient expression is required to commit multipotent progenitor cells to an endocrine fate, leading to the formation of insulin-producing beta cells and other hormone-secreting cells (NCBI Gene 50674). While the protein itself is the functional unit, Neurog3 mRNA is frequently discussed in the context of regenerative medicine and gene therapy, where synthetic mRNA transcripts are delivered to non-endocrine tissues to induce reprogramming into functional beta-like cells for the treatment of Type 1 Diabetes (PubMed PMID: 18753626). Mutations in the NEUROG3 gene are clinically significant, causing rare conditions such as congenital malabsorptive diarrhea (enteric anendocrinosis) and neonatal diabetes due to the failure of endocrine cell development (PubMed PMID: 16415871). Currently, there are no approved small-molecule drugs targeting NEUROG3; however, it remains a high-priority target for cell-replacement therapies and in vivo reprogramming strategies using viral vectors or lipid nanoparticle-encapsulated mRNA.

Other names
NGN3bHLHa7Math4BAtonal homolog 4BProtein atonal homolog 4BClass A basic helix-loop-helix transcription factor 7
02

Mechanism of action

Induction of endocrine progenitor differentiation via transcriptional activation of downstream targets like NeuroD1 and Pax4 to drive lineage commitment (PubMed PMID: 18753626).

03

Biological functions

Endocrine cell differentiationPancreatic developmentEnteroendocrine cell differentiationCell fate commitmentTranscriptional regulation
04

Disease associations

Type 1 diabetes mellitusType 2 diabetes mellitusCongenital malabsorptive diarrheaEnteric anendocrinosis
05

Safety considerations

Risk of ectopic endocrine cell formation in non-target tissuesPotential for tumorigenesis or uncontrolled cell proliferation if expression is not transientImmunogenicity associated with viral or lipid nanoparticle delivery systemsOff-target effects of cellular reprogramming
06

Biomarkers

NEUROG3 mRNA expression levelsChromogranin AInsulinGlucagon

Beyond the preview

Go deeper on Neurogenin-3 (NEUROG3) (NEUROG3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurogenin-3 (NEUROG3) (NEUROG3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call